Fig. 2
From: The evolution of alternative splicing in glioblastoma under therapy
a The frequencies of neojunctions identified by Kahles et al. [2] across the domains of cell-surface proteins. b The frequencies of neojunctions in the extracellular domains of cell-surface proteins and in neoplastic cells vs. non-malignant glia, immune, and endothelial cells. c The frequencies of expression of neojunction sequences in human GBM neoplastic cells in Smart-seq2 scRNA-seq data. d The frequencies of neojunctions across the GBM and pan-cancer populations, as assessed from The Cancer Genome Atlas (TCGA) RNA-seq data